Gleevec Increases Survival Times in Patients With GIST

by Kathy Jones on  June 6, 2011 at 6:31 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

Using Novartis' cancer drug Gleevec for up to three years after surgery, instead of the commonly followed practice of just one year, could increase the survival period of patients suffering from gastrointestinal stromal tumors (GIST).
 Gleevec Increases Survival Times in Patients With GIST
Gleevec Increases Survival Times in Patients With GIST

The study, led by Dr Heikki Joensuu from University of Helsinki, Finland, found that taking Gleevec for three years after surgery increased the five year survival chances of the patients by 55 percent compared to those who took the drug for just one year.

Over 400 patients took part in the study that was presented at the annual meeting of the American Society of Clinical Oncology in Chicago. The researchers found that at the end of five years, more than 65 percent of those who had taken the drug for three years were cancer-free compared to 48 percent of those who took it for one year.

"I tend to think three year treatment will be the standard. I think these data are pretty compelling", Joensuu said.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

Advertisement

News Category

News Archive